Skip to main navigation Skip to search Skip to main content

Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer

  • Carlos A. Castaneda
  • , Henry L. Gómez
  • Instituto Nacional de Enfermedades Neoplásicas Eduardo Cáceres Graziani

Research output: Contribution to journalArticlepeer-review

Abstract

Resistance to chemotherapy is a complex and very frequent problem in the treatment of breast cancer. It is associated with a poor prognosis and short overall survival. We report a patient with advanced breast cancer without response to anthracyclines or taxanes but who controlled the disease for 15 months with the combination of ixabepilone and capecitabine.

Original languageEnglish
Pages (from-to)E1-E3
JournalClinical Breast Cancer
Volume9
Issue number4
DOIs
StatePublished - 2009
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Beta-tubulin
  • Capecitabine
  • Ixabepilone
  • MDR1

Cite this